Jan Medical is partnering with software-driven medtech firm Brainlab to gain FDA clearances via 2 clinical trials, the companies announced.
As part of the collaboration, Brainlab will add a representative to Jan Medical’s board, the companies said in a press release.
Mountain View, Calif.-based Jan Medical makes the the Nautilus NeuroWave, a portable, non-invasive brain sensing system designed to detect abnormal neurological conditions, including ischemic stroke, vasospasm, and concussion.
"Our Nautilus NeuroWave system is designed to give healthcare providers a reliable non-invasive device designed to detect cerebral abnormalities in clinical settings where conventional imaging technologies are not effective or in the case of concussion, non-existent," president & CEO Paul Lovoi said prepared remarks. "As a result, patient outcomes will be enhanced, as healthcare providers will have clinically relevant and timely information to treat their patients faster, at lower cost, and with less risk."
Jan Medical closed a vasospasm study at UCSF Hospital using Nautilus NeuroWave for patients recovering from subarachnoid hemorrhagic, who can suffer symptomatic spasm within the cerebral vasculature leading to cerebral infarction, the company said.
The device is also being evaluated for its ability to detect and track recovery from sports-related concussion in an investigator-led clinical trial at Stanford University, according to a press release.
Munich, Germany-based Brainlab’s technology is used in treatments for neurosurgery, radiation oncology, orthopedics, ENT, CMF, spine, and trauma, the company said.
"Partnering with and investing in an innovative company, with goals aligned with Brainlab’s vision, is an exciting opportunity for us," Brainlab president & CEO Stefan Vilsmeier said. "Jan Medical’s specialization in adjacent markets to our own provides us a vehicle to expand our footprint in the neuro-tech space."
